Vanguard Group Inc. lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,562,165 shares of the company's stock after buying an additional 28,573 shares during the period. Vanguard Group Inc. owned about 12.01% of Omnicell worth $247,628,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of OMCL. Smartleaf Asset Management LLC lifted its stake in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp lifted its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares during the period. First Horizon Advisors Inc. lifted its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the period. KBC Group NV boosted its stake in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after acquiring an additional 778 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Omnicell by 307.8% in the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock worth $159,000 after acquiring an additional 2,699 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms have commented on OMCL. JPMorgan Chase & Co. decreased their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Bank of America decreased their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $51.00.
Get Our Latest Stock Report on Omnicell
Omnicell Trading Down 4.9 %
OMCL traded down $1.61 during trading on Thursday, hitting $31.08. The company's stock had a trading volume of 766,752 shares, compared to its average volume of 528,176. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.75. The stock has a market cap of $1.45 billion, a PE ratio of 115.12, a PEG ratio of 7.53 and a beta of 0.78. The firm's 50 day moving average price is $36.59 and its 200-day moving average price is $41.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.
Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.
Omnicell Company Profile
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Articles
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
